Ubs Group Ag Forma Therapeutics Holdings, Inc. Transaction History

Ubs Group Ag

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	BUY	$7.12 - $20.24 $1.28 Million - $3.63 Million	179,496 Added 415.35%	222,712 $4.44 Million
Q2 2022 Aug 10, 2022	SELL	$5.1 - $10.0 $366,735 - $719,090	-71,909 Reduced 62.46%	43,216 $298,000
Q1 2022 May 16, 2022	BUY	$8.34 - $14.69 $338,528 - $596,281	40,591 Added 54.46%	115,125 $1.07 Million
Q4 2021 Feb 14, 2022	BUY	$13.6 - $24.89 $717,454 - $1.31 Million	52,754 Added 242.21%	74,534 $1.06 Million
Q3 2021 Nov 15, 2021	BUY	$21.22 - $25.7 $293,366 - $355,302	13,825 Added 173.79%	21,780 $505,000
Q2 2021 Aug 13, 2021	SELL	$22.86 - $30.95 $957,513 - $1.3 Million	-41,886 Reduced 84.04%	7,955 $198,000
Q1 2021 May 12, 2021	BUY	$24.58 - $42.82 $1.18 Million - $2.06 Million	48,066 Added 2707.94%	49,841 $1.4 Million
Q4 2020 Feb 11, 2021	BUY	$34.9 - $51.08 $52,629 - $77,028	1,508 Added 564.79%	1,775 $62,000
Q3 2020 Nov 12, 2020	SELL	$32.95 - $50.25 $5,601 - $8,542	-170 Reduced 38.9%	267 $13,000
Q2 2020 Jul 31, 2020	BUY	$39.0 - $46.49 $17,043 - $20,316	437 New	437 $20,000

26.5K

Ticker FMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,860,400
Market Cap $958M
Description
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobin...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.